Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Halofuginone

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Halofuginone: Sponsors, patents, clinical trial progress

Halofuginone is an investigational drug.

There have been 5 clinical trials for Halofuginone. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2003.

The most common disease conditions in clinical trials are Muscular Dystrophy, Duchenne, Muscular Dystrophies, and Sarcoma, Kaposi. The leading clinical trial sponsors are Akashi Therapeutics, National Cancer Institute (NCI), and European Organisation for Research and Treatment of Cancer - EORTC.

Recent Clinical Trials for Halofuginone
HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02Akashi TherapeuticsPhase 2
Open Label Extension Study of HT-100 in Patients With DMDAkashi TherapeuticsPhase 2
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyAkashi TherapeuticsPhase 1/Phase 2

See all Halofuginone clinical trials

Clinical Trial Summary for Halofuginone

Top disease conditions for Halofuginone
Top clinical trial sponsors for Halofuginone

See all Halofuginone clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.